Humoral Immune Memory to Hepatitis B Vaccine after Primary Vaccination of Children and Adolescents in Assiut, Egypt

Objectives: We sought to assess the prevalence of hepatitis B virus (HBV) seroprotection among vaccinated children in the Assiut governorate, Egypt, and assess a booster dose immune memory response among non-seroprotected children. Methods: Using a multistage cluster sample, 566 children were recrui...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oman medical journal 2020-09, Vol.35 (5), p.1-9
Hauptverfasser: Hassanain , Amal I, El Serougy , Safaa M, El Hariri , Hazem M, Sami , Samia M, Salama , Iman I, Said , Zeinab N, Salama , Somaia I, Abdel Mohsen , Aida M, Fouad , Walaa A, Emam , Hanaa M, Hemeda , Samia A, El Etreby , Lobna A
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 9
container_issue 5
container_start_page 1
container_title Oman medical journal
container_volume 35
creator Hassanain , Amal I
El Serougy , Safaa M
El Hariri , Hazem M
Sami , Samia M
Salama , Iman I
Said , Zeinab N
Salama , Somaia I
Abdel Mohsen , Aida M
Fouad , Walaa A
Emam , Hanaa M
Hemeda , Samia A
El Etreby , Lobna A
description Objectives: We sought to assess the prevalence of hepatitis B virus (HBV) seroprotection among vaccinated children in the Assiut governorate, Egypt, and assess a booster dose immune memory response among non-seroprotected children. Methods: Using a multistage cluster sample, 566 children were recruited from three clusters: one urban and two rural. Children were aged from nine months to 16 years old. All participants received the full three doses of the compulsory HBV vaccine during infancy. Serum hepatitis B surface antigen (HBsAg), total anti-hepatitis B core (anti-HBc) antibodies, and quantitative detection of anti-HBs were measured using enzyme-linked immunosorbent assay. Repeatedly positive samples for HBsAg/anti-HBc were submitted for quantitative HBV DNA detection using real-time polymerase chain reaction. Non-seroprotective participants (anti-HBs < 10 IU/L) were given a booster dose of HBV vaccine. Two weeks later, a blood sample was taken from each child to assess an anamnestic response. Results: The seroprotection rate was 53.2%, and only two children had HBV breakthrough infection (0.4%) with positive serum anti-HBc and HBV DNA. Age was the only significant predictor for non-seroprotection with an adjusted odds ratio (OR) of 3.2, 9.4, and 9.9 among children aged 5-10, 11-15, and > 15 years, respectively, compared to younger children (p < 0.001). About 85% of non-seroprotected children developed an anamnestic response after receiving the booster dose, and 84.3% of responders had a good response (>= 100 IU/L). Undetectable pre-booster titer was found to be the only risk factor for non-response to booster with OR = 3.2 (p < 0.010). About 95.7% of children who were not responding to booster dose developed immune response after receiving the three doses of HBV vaccine. Conclusions: Older age of children was the only significant predictor for HBV non-seroprotection. High anamnestic response rate signifies the presence of immune memory with long-term protection despite the waning of anti-HBs over time. However, some children with pre-booster undetectable anti-HBs titers may be unable to develop anamnestic response, and a second vaccination series might be necessary for HBV protection for these children.
doi_str_mv 10.5001/omj.2020.117
format Article
fullrecord <record><control><sourceid>pubmed_rmit_</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7538637</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><informt_id>10.3316/informit.495786117864638</informt_id><doaj_id>oai_doaj_org_article_cbb4e5e4f68848dfa7318ed033c4ff78</doaj_id><sourcerecordid>33083033</sourcerecordid><originalsourceid>FETCH-LOGICAL-a4697-8fe2a9f696636d48b7b914d8273e3a037710880696214025fbd5a10e37b530983</originalsourceid><addsrcrecordid>eNpVUU1vEzEUXCEQjUpvnJF_QBNsP68_LkghKiRSERwA9WZ513biaHcdrR2k_nu8XeiHL5bfjGfee1NV7wle1RiTj7E_riimeEWIeFUtKBZ4WVPMXlcLopRaCi7vLqqrlI64HFBUAX1bXQBgCRhgUaXtuY-j6dCu78-DQ99ced6jHNHWnUwOOST0Gf02bRsKanx2I_oxht4U0lwtpDig6NHmEDo7ugGZwaK1jZ1LrRtyQmFA65TCOV-jm_39Kb-r3njTJXf1776sfn25-bnZLm-_f91t1rdLw7gSS-kdNcpzxTlwy2QjGkWYlVSAA4NBCIKlxAWnhGFa-8bWhmAHoqkBKwmX1W7WtdEc9WnuWkcT9EMhjnttxhzazum2aZirHfNcSiatNwKIdLasqGXei0nr06x1Oje9s9NgZWsvRF8iQzjoffyjRQ2SgygC17NAO8aURucf_xKspyx1yVJPWeqSZaF_eO73SP6fXCHczYSxD1m3setcOyWRjiYnnZwZ24MOg48P-DSrjUGbJk1-AIQ_gUzVQvLiKjnjIJ-8Tdeb4fBsTFqsOYO_eOrEAA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Humoral Immune Memory to Hepatitis B Vaccine after Primary Vaccination of Children and Adolescents in Assiut, Egypt</title><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Hassanain , Amal I ; El Serougy , Safaa M ; El Hariri , Hazem M ; Sami , Samia M ; Salama , Iman I ; Said , Zeinab N ; Salama , Somaia I ; Abdel Mohsen , Aida M ; Fouad , Walaa A ; Emam , Hanaa M ; Hemeda , Samia A ; El Etreby , Lobna A</creator><creatorcontrib>Hassanain , Amal I ; El Serougy , Safaa M ; El Hariri , Hazem M ; Sami , Samia M ; Salama , Iman I ; Said , Zeinab N ; Salama , Somaia I ; Abdel Mohsen , Aida M ; Fouad , Walaa A ; Emam , Hanaa M ; Hemeda , Samia A ; El Etreby , Lobna A</creatorcontrib><description>Objectives: We sought to assess the prevalence of hepatitis B virus (HBV) seroprotection among vaccinated children in the Assiut governorate, Egypt, and assess a booster dose immune memory response among non-seroprotected children. Methods: Using a multistage cluster sample, 566 children were recruited from three clusters: one urban and two rural. Children were aged from nine months to 16 years old. All participants received the full three doses of the compulsory HBV vaccine during infancy. Serum hepatitis B surface antigen (HBsAg), total anti-hepatitis B core (anti-HBc) antibodies, and quantitative detection of anti-HBs were measured using enzyme-linked immunosorbent assay. Repeatedly positive samples for HBsAg/anti-HBc were submitted for quantitative HBV DNA detection using real-time polymerase chain reaction. Non-seroprotective participants (anti-HBs &lt; 10 IU/L) were given a booster dose of HBV vaccine. Two weeks later, a blood sample was taken from each child to assess an anamnestic response. Results: The seroprotection rate was 53.2%, and only two children had HBV breakthrough infection (0.4%) with positive serum anti-HBc and HBV DNA. Age was the only significant predictor for non-seroprotection with an adjusted odds ratio (OR) of 3.2, 9.4, and 9.9 among children aged 5-10, 11-15, and &gt; 15 years, respectively, compared to younger children (p &lt; 0.001). About 85% of non-seroprotected children developed an anamnestic response after receiving the booster dose, and 84.3% of responders had a good response (&gt;= 100 IU/L). Undetectable pre-booster titer was found to be the only risk factor for non-response to booster with OR = 3.2 (p &lt; 0.010). About 95.7% of children who were not responding to booster dose developed immune response after receiving the three doses of HBV vaccine. Conclusions: Older age of children was the only significant predictor for HBV non-seroprotection. High anamnestic response rate signifies the presence of immune memory with long-term protection despite the waning of anti-HBs over time. However, some children with pre-booster undetectable anti-HBs titers may be unable to develop anamnestic response, and a second vaccination series might be necessary for HBV protection for these children.</description><identifier>ISSN: 1999-768X</identifier><identifier>EISSN: 2070-5204</identifier><identifier>DOI: 10.5001/omj.2020.117</identifier><identifier>PMID: 33083033</identifier><language>eng</language><publisher>Muscat - Oman: Oman Medical Specialty Board</publisher><subject>ADOLESCENTS ; ANTIBODIES ; Care ; CHILDREN ; EGYPT ; HEPATITIS ; hepatitis b antibodies ; hepatitis b surface antigens ; Hepatitis B virus ; Immunization ; Immunoglobulins ; Infants ; Original ; secondary ; VACCINATION ; إلتهاب الكبد ; الأجسام المضادة ; الأطفال ; التطعيم ; المراهقون ; مصر</subject><ispartof>Oman medical journal, 2020-09, Vol.35 (5), p.1-9</ispartof><rights>The OMJ is Published Bimonthly and Copyrighted 2020 by the OMSB.</rights><rights>The OMJ is Published Bimonthly and Copyrighted 2020 by the OMSB. 2020 Oman Medical Specialty Board</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a4697-8fe2a9f696636d48b7b914d8273e3a037710880696214025fbd5a10e37b530983</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttps://static.almanhal.com/covers/titl/230364/cover-lg.jpg</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538637/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538637/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33083033$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hassanain , Amal I</creatorcontrib><creatorcontrib>El Serougy , Safaa M</creatorcontrib><creatorcontrib>El Hariri , Hazem M</creatorcontrib><creatorcontrib>Sami , Samia M</creatorcontrib><creatorcontrib>Salama , Iman I</creatorcontrib><creatorcontrib>Said , Zeinab N</creatorcontrib><creatorcontrib>Salama , Somaia I</creatorcontrib><creatorcontrib>Abdel Mohsen , Aida M</creatorcontrib><creatorcontrib>Fouad , Walaa A</creatorcontrib><creatorcontrib>Emam , Hanaa M</creatorcontrib><creatorcontrib>Hemeda , Samia A</creatorcontrib><creatorcontrib>El Etreby , Lobna A</creatorcontrib><title>Humoral Immune Memory to Hepatitis B Vaccine after Primary Vaccination of Children and Adolescents in Assiut, Egypt</title><title>Oman medical journal</title><addtitle>Oman Med J</addtitle><description>Objectives: We sought to assess the prevalence of hepatitis B virus (HBV) seroprotection among vaccinated children in the Assiut governorate, Egypt, and assess a booster dose immune memory response among non-seroprotected children. Methods: Using a multistage cluster sample, 566 children were recruited from three clusters: one urban and two rural. Children were aged from nine months to 16 years old. All participants received the full three doses of the compulsory HBV vaccine during infancy. Serum hepatitis B surface antigen (HBsAg), total anti-hepatitis B core (anti-HBc) antibodies, and quantitative detection of anti-HBs were measured using enzyme-linked immunosorbent assay. Repeatedly positive samples for HBsAg/anti-HBc were submitted for quantitative HBV DNA detection using real-time polymerase chain reaction. Non-seroprotective participants (anti-HBs &lt; 10 IU/L) were given a booster dose of HBV vaccine. Two weeks later, a blood sample was taken from each child to assess an anamnestic response. Results: The seroprotection rate was 53.2%, and only two children had HBV breakthrough infection (0.4%) with positive serum anti-HBc and HBV DNA. Age was the only significant predictor for non-seroprotection with an adjusted odds ratio (OR) of 3.2, 9.4, and 9.9 among children aged 5-10, 11-15, and &gt; 15 years, respectively, compared to younger children (p &lt; 0.001). About 85% of non-seroprotected children developed an anamnestic response after receiving the booster dose, and 84.3% of responders had a good response (&gt;= 100 IU/L). Undetectable pre-booster titer was found to be the only risk factor for non-response to booster with OR = 3.2 (p &lt; 0.010). About 95.7% of children who were not responding to booster dose developed immune response after receiving the three doses of HBV vaccine. Conclusions: Older age of children was the only significant predictor for HBV non-seroprotection. High anamnestic response rate signifies the presence of immune memory with long-term protection despite the waning of anti-HBs over time. However, some children with pre-booster undetectable anti-HBs titers may be unable to develop anamnestic response, and a second vaccination series might be necessary for HBV protection for these children.</description><subject>ADOLESCENTS</subject><subject>ANTIBODIES</subject><subject>Care</subject><subject>CHILDREN</subject><subject>EGYPT</subject><subject>HEPATITIS</subject><subject>hepatitis b antibodies</subject><subject>hepatitis b surface antigens</subject><subject>Hepatitis B virus</subject><subject>Immunization</subject><subject>Immunoglobulins</subject><subject>Infants</subject><subject>Original</subject><subject>secondary</subject><subject>VACCINATION</subject><subject>إلتهاب الكبد</subject><subject>الأجسام المضادة</subject><subject>الأطفال</subject><subject>التطعيم</subject><subject>المراهقون</subject><subject>مصر</subject><issn>1999-768X</issn><issn>2070-5204</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVUU1vEzEUXCEQjUpvnJF_QBNsP68_LkghKiRSERwA9WZ513biaHcdrR2k_nu8XeiHL5bfjGfee1NV7wle1RiTj7E_riimeEWIeFUtKBZ4WVPMXlcLopRaCi7vLqqrlI64HFBUAX1bXQBgCRhgUaXtuY-j6dCu78-DQ99ced6jHNHWnUwOOST0Gf02bRsKanx2I_oxht4U0lwtpDig6NHmEDo7ugGZwaK1jZ1LrRtyQmFA65TCOV-jm_39Kb-r3njTJXf1776sfn25-bnZLm-_f91t1rdLw7gSS-kdNcpzxTlwy2QjGkWYlVSAA4NBCIKlxAWnhGFa-8bWhmAHoqkBKwmX1W7WtdEc9WnuWkcT9EMhjnttxhzazum2aZirHfNcSiatNwKIdLasqGXei0nr06x1Oje9s9NgZWsvRF8iQzjoffyjRQ2SgygC17NAO8aURucf_xKspyx1yVJPWeqSZaF_eO73SP6fXCHczYSxD1m3setcOyWRjiYnnZwZ24MOg48P-DSrjUGbJk1-AIQ_gUzVQvLiKjnjIJ-8Tdeb4fBsTFqsOYO_eOrEAA</recordid><startdate>20200901</startdate><enddate>20200901</enddate><creator>Hassanain , Amal I</creator><creator>El Serougy , Safaa M</creator><creator>El Hariri , Hazem M</creator><creator>Sami , Samia M</creator><creator>Salama , Iman I</creator><creator>Said , Zeinab N</creator><creator>Salama , Somaia I</creator><creator>Abdel Mohsen , Aida M</creator><creator>Fouad , Walaa A</creator><creator>Emam , Hanaa M</creator><creator>Hemeda , Samia A</creator><creator>El Etreby , Lobna A</creator><general>Oman Medical Specialty Board</general><general>OMJ</general><scope>~6Z</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20200901</creationdate><title>Humoral Immune Memory to Hepatitis B Vaccine after Primary Vaccination of Children and Adolescents in Assiut, Egypt</title><author>Hassanain , Amal I ; El Serougy , Safaa M ; El Hariri , Hazem M ; Sami , Samia M ; Salama , Iman I ; Said , Zeinab N ; Salama , Somaia I ; Abdel Mohsen , Aida M ; Fouad , Walaa A ; Emam , Hanaa M ; Hemeda , Samia A ; El Etreby , Lobna A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a4697-8fe2a9f696636d48b7b914d8273e3a037710880696214025fbd5a10e37b530983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>ADOLESCENTS</topic><topic>ANTIBODIES</topic><topic>Care</topic><topic>CHILDREN</topic><topic>EGYPT</topic><topic>HEPATITIS</topic><topic>hepatitis b antibodies</topic><topic>hepatitis b surface antigens</topic><topic>Hepatitis B virus</topic><topic>Immunization</topic><topic>Immunoglobulins</topic><topic>Infants</topic><topic>Original</topic><topic>secondary</topic><topic>VACCINATION</topic><topic>إلتهاب الكبد</topic><topic>الأجسام المضادة</topic><topic>الأطفال</topic><topic>التطعيم</topic><topic>المراهقون</topic><topic>مصر</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hassanain , Amal I</creatorcontrib><creatorcontrib>El Serougy , Safaa M</creatorcontrib><creatorcontrib>El Hariri , Hazem M</creatorcontrib><creatorcontrib>Sami , Samia M</creatorcontrib><creatorcontrib>Salama , Iman I</creatorcontrib><creatorcontrib>Said , Zeinab N</creatorcontrib><creatorcontrib>Salama , Somaia I</creatorcontrib><creatorcontrib>Abdel Mohsen , Aida M</creatorcontrib><creatorcontrib>Fouad , Walaa A</creatorcontrib><creatorcontrib>Emam , Hanaa M</creatorcontrib><creatorcontrib>Hemeda , Samia A</creatorcontrib><creatorcontrib>El Etreby , Lobna A</creatorcontrib><collection>Al Manhal All Journals Collection</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Oman medical journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hassanain , Amal I</au><au>El Serougy , Safaa M</au><au>El Hariri , Hazem M</au><au>Sami , Samia M</au><au>Salama , Iman I</au><au>Said , Zeinab N</au><au>Salama , Somaia I</au><au>Abdel Mohsen , Aida M</au><au>Fouad , Walaa A</au><au>Emam , Hanaa M</au><au>Hemeda , Samia A</au><au>El Etreby , Lobna A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Humoral Immune Memory to Hepatitis B Vaccine after Primary Vaccination of Children and Adolescents in Assiut, Egypt</atitle><jtitle>Oman medical journal</jtitle><addtitle>Oman Med J</addtitle><date>2020-09-01</date><risdate>2020</risdate><volume>35</volume><issue>5</issue><spage>1</spage><epage>9</epage><pages>1-9</pages><issn>1999-768X</issn><eissn>2070-5204</eissn><abstract>Objectives: We sought to assess the prevalence of hepatitis B virus (HBV) seroprotection among vaccinated children in the Assiut governorate, Egypt, and assess a booster dose immune memory response among non-seroprotected children. Methods: Using a multistage cluster sample, 566 children were recruited from three clusters: one urban and two rural. Children were aged from nine months to 16 years old. All participants received the full three doses of the compulsory HBV vaccine during infancy. Serum hepatitis B surface antigen (HBsAg), total anti-hepatitis B core (anti-HBc) antibodies, and quantitative detection of anti-HBs were measured using enzyme-linked immunosorbent assay. Repeatedly positive samples for HBsAg/anti-HBc were submitted for quantitative HBV DNA detection using real-time polymerase chain reaction. Non-seroprotective participants (anti-HBs &lt; 10 IU/L) were given a booster dose of HBV vaccine. Two weeks later, a blood sample was taken from each child to assess an anamnestic response. Results: The seroprotection rate was 53.2%, and only two children had HBV breakthrough infection (0.4%) with positive serum anti-HBc and HBV DNA. Age was the only significant predictor for non-seroprotection with an adjusted odds ratio (OR) of 3.2, 9.4, and 9.9 among children aged 5-10, 11-15, and &gt; 15 years, respectively, compared to younger children (p &lt; 0.001). About 85% of non-seroprotected children developed an anamnestic response after receiving the booster dose, and 84.3% of responders had a good response (&gt;= 100 IU/L). Undetectable pre-booster titer was found to be the only risk factor for non-response to booster with OR = 3.2 (p &lt; 0.010). About 95.7% of children who were not responding to booster dose developed immune response after receiving the three doses of HBV vaccine. Conclusions: Older age of children was the only significant predictor for HBV non-seroprotection. High anamnestic response rate signifies the presence of immune memory with long-term protection despite the waning of anti-HBs over time. However, some children with pre-booster undetectable anti-HBs titers may be unable to develop anamnestic response, and a second vaccination series might be necessary for HBV protection for these children.</abstract><cop>Muscat - Oman</cop><pub>Oman Medical Specialty Board</pub><pmid>33083033</pmid><doi>10.5001/omj.2020.117</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1999-768X
ispartof Oman medical journal, 2020-09, Vol.35 (5), p.1-9
issn 1999-768X
2070-5204
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7538637
source DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects ADOLESCENTS
ANTIBODIES
Care
CHILDREN
EGYPT
HEPATITIS
hepatitis b antibodies
hepatitis b surface antigens
Hepatitis B virus
Immunization
Immunoglobulins
Infants
Original
secondary
VACCINATION
إلتهاب الكبد
الأجسام المضادة
الأطفال
التطعيم
المراهقون
مصر
title Humoral Immune Memory to Hepatitis B Vaccine after Primary Vaccination of Children and Adolescents in Assiut, Egypt
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T08%3A56%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_rmit_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Humoral%20Immune%20Memory%20to%20Hepatitis%20B%20Vaccine%20after%20Primary%20Vaccination%20of%20Children%20and%20Adolescents%20in%20Assiut,%20Egypt&rft.jtitle=Oman%20medical%20journal&rft.au=Hassanain%20,%20Amal%20I&rft.date=2020-09-01&rft.volume=35&rft.issue=5&rft.spage=1&rft.epage=9&rft.pages=1-9&rft.issn=1999-768X&rft.eissn=2070-5204&rft_id=info:doi/10.5001/omj.2020.117&rft_dat=%3Cpubmed_rmit_%3E33083033%3C/pubmed_rmit_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/33083033&rft_informt_id=10.3316/informit.495786117864638&rft_doaj_id=oai_doaj_org_article_cbb4e5e4f68848dfa7318ed033c4ff78&rfr_iscdi=true